Table 2. PCR-unadjusted treatment response of study patients treated with artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL)
PCR-unadjusted Treatment responses | Artesunate-amodiaquine | Artemether-lumefantrine | ||||
|---|---|---|---|---|---|---|
Malabo (N = 88) n (%) | Bata (N = 88) n (%) | Ebibeyin (N = 88) n (%) | Malabo (N = 50) n (%) | Bata (N = 88) n (%) | Ebibeyin (N = 88) n (%) | |
LCF | 0 | 1 (1.2) | 2 (2.5) | 0 | 0 | 0 |
LPF | 0 | 2 (2.5) | 7 (8.8) | 3 (7.1) | 4 (4.7) | 22 (26.5) |
ACPR | 67 (100) | 78 (96.3) | 71 (88.8) | 39 (92.9) | 81 (95.3) | 61 (73.5) |
Total per-protocol | 67 | 81 | 80 | 42 | 85 | 83 |
Lost follow-up/withdrawn | 21 (23.9) | 7 (8) | 8 (9.1) | 8 (16) | 3 (3.4) | 5 (5.7) |
Kaplan Meier: cure rate | 67 (100) | 78 (96.3) | 71 (88.8) | 39 (92.9) | 81 (95.3) | 61 (73.5) |